Mcvean
Charles Mcvean, Memphis, TN US
Patent application number | Description | Published |
---|---|---|
20120290160 | ELECTRIC VEHICLE POWER REGULATING CONTROL METHOD WITH MANUAL-ASSIST HYBRID MODES - We disclose a method for controlling power to a human electric hybrid vehicle that creates a superior ride compared to electric vehicles of the prior art. The present invention employs a large motor that can assist a rider at slower speeds but limits the amount of power that the motor can produce at greater speeds. We also disclose a controller and a human electric hybrid bicycle capable of utilizing the claimed method. | 11-15-2012 |
20140129072 | ELECTRIC VEHICLE POWER REGULATING CONTROL METHOD WITH MANUAL-ASSIST HYBRID MODES - We disclose a method for controlling power to a human electric hybrid vehicle that creates a superior ride compared to electric vehicles of the prior art. The present invention employs a large motor that can assist a rider at slower speeds but limits the amount of power that the motor can produce at greater speeds. We also disclose a controller and a human electric hybrid bicycle capable of utilizing the claimed method. | 05-08-2014 |
Gilean Mcvean, Oxford GB
Patent application number | Description | Published |
---|---|---|
20140019109 | ALLELIC DETERMINATION - A method of determining an allelic type of a specific individual, comprising: | 01-16-2014 |
Jason Mcvean, Calgary CA
Patent application number | Description | Published |
---|---|---|
20090070158 | METHOD APPARATUS AND SYSTEM FOR VISUALIZATION OF PROBABILISTIC MODELS - A method, apparatus, computer system and a program storage device for modeling a business process to assess risk is provided. A preferred embodiment of the method includes the steps of: (a) creating a high level model for the business process, (b) modeling a calculation algorithm for the business process; and (c) testing the model; wherein one or more views are used in each of steps (a), (b) and (c); and wherein the pattern technique of identifying and visualizing uncertainty is used in each of steps (a), (b) and (c), in increasing detail at each successive step. | 03-12-2009 |
Kirsty Margaret Mcvean, Bath GB
Patent application number | Description | Published |
---|---|---|
20140370248 | STRAY LIGHT RESISTANCE OF UV INKJET INKS - An energy curable inkjet ink includes a nitroxy inhibitor, a compound having an ethylenic unsaturated bond, a photoinitiator, a coloring agent, and a stray light resistance index of at least 7. A method of preparing an energy curable inkjet ink with stray light resistance includes providing a nitroxy inhibitor; providing a mixture of a compound having an ethylenic unsaturated bond, and a photoinitiator, and a coloring agent; combining the nitroxy inhibitor and the mixture to obtain the energy curable inkjet ink and thereby to increase a stray light resistance index of the energy curable inkjet ink to at least 7. | 12-18-2014 |
Maralee Mcvean, Seattle, WA US
Patent application number | Description | Published |
---|---|---|
20120258908 | OLIGOADENYLATE SYNTHETASE (OAS) - The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention. | 10-11-2012 |
20130157293 | PHARMACEUTICAL MANUFACTURING METHODS - The invention describes methods for manufacturing oligoadenylate synthetase (OAS) proteins for use as active pharmaceutical ingredients in pharmaceutical compositions. A manufacturing method is described that produces large quantities of concentrated, highly active OAS protein for use in pharmaceutical compositions for the treatment of a variety of diseases including viral infection. Methods for monitoring and validating the manufacturing process are also described. | 06-20-2013 |
20140005101 | Oligoadenylate Synthetase (OAS) | 01-02-2014 |
20140005102 | Oligoadenylate Synthetase (OAS) | 01-02-2014 |